Pine Labs Raises $75-100 Million in Fresh Funding at $2 Billion Valuation (Economic Times) Pine Labs has raised $75-$100 million led by US-based billionaire...
Keep Reading →
December 21 - Hedge Funds, Insider Trading - Comments
Bill Ackman Makes More Layoffs at His Pershing Square Hedge Fund (CNBC) Billionaire hedge fund manager William Ackman, whose investment assets have shrunk...
Keep Reading →
June 27 - Hedge Funds, Insider Trading - Comments
‘Capitalism May Need Modernizing,’ Says Billionaire Hedge Fund Manager Paul Tudor Jones (CNBC) The 50-year-old definition of capitalism in...
Keep Reading →
June 12 - Hedge Funds, Insider Trading - Comments
Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts. Here’s a look at these...
Keep Reading →
March 1 - News, Stock Analysis - Comments
Right then, it’s time to take a look at who moved during the start of this week, and what’s driving the action in the biotech sector. In a continuation...
Keep Reading →
December 6 - Market Movers, News, Stock Analysis - Comments
When things go well in biotech, it can be a great ride. When things repeatedly go well, however, it can be easy to forget how quickly, and how frequently...
Keep Reading →
September 16 - News, Stock Analysis - Comments
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) gained considerably at the end of last week on the back of a data release from its ongoing type 1 diabetes...
Keep Reading →
September 13 - News, Stock Analysis - Comments
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) are up by more than 20% in early trading, following positive Phase 2 reports on HTX-011, an anesthetic...
Keep Reading →
September 23 - Hedge Funds, News - Comments
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) are flying high today, gaining nearly 60% on Monday, as the company announced positive results for...
Keep Reading →
August 3 - Hedge Funds, News - Comments
Is Nektar Therapeutics (NASDAQ:NKTR) a good investment? Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment...
Keep Reading →
September 17 - News - Comments
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age. Although there are In excess of 8,000 hedge funds...
Keep Reading →
September 11 - News - Comments
Should PDL BioPharma Inc. (NASDAQ:PDLI) investors track the following data? In the eyes of many market players, hedge funds are seen as overrated, old...
Keep Reading →
September 3 - News - Comments
What should a smart Santarus, Inc. (NASDAQ:SNTS) investor do? In the financial world, there are a multitude of gauges investors can use to watch publicly...
Keep Reading →
August 30 - News - Comments
Is it smart to be bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT)? If you were to ask many of your fellow readers, hedge funds are seen as overrated...
Keep Reading →
August 30 - News - Comments
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it’s related to efficacy; sometimes, it’s safety related. Most of the...
Keep Reading →
August 30 - News - Comments
Are you curious what the richest investors think about VIVUS, Inc. (NASDAQ:VVUS)? In the 21st century investor’s toolkit, there are dozens of metrics...
Keep Reading →
August 22 - News - Comments
Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at...
Keep Reading →
July 24 - News - Comments
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds’ portfolio at the end of March. NKTR has experienced a decrease in support from the world...
Keep Reading →
June 12 - News - Comments
Regardless of Anchor, Things Are Looking Up! It has been a rough year for Amarin Corporation plc (ADR) (NASDAQ:AMRN) and its long-term investors. The...
Keep Reading →
June 3 - News - Comments
Santarus, Inc. (NASDAQ:SNTS) investors should pay attention to a decrease in hedge fund interest in recent months. If you’d ask most shareholders...
Keep Reading →
June 3 - News - Comments
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds’ portfolio at the end of March. SRPT shareholders have witnessed an increase in enthusiasm...
Keep Reading →
June 3 - News - Comments
The global economy is still going through the initial stages of recovery and waiting on positive news from European markets. This bad economy has created...
Keep Reading →
March 19 - Insider Trading - Comments
